Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment

Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment

Background: Progressive multifocal leukoencephalopathy (PML) caused by the JC virus is the main limitation to the use of disease modifying therapies for treatment of multiple sclerosis (MS). Methods: To assess the PML risk in course of ocrelizumab, urine and blood samples were collected from 42 MS p...

Full description

Bibliographic Details
Main Authors: Carla Prezioso, Alfonso Grimaldi, Doriana Landi, Carolina Gabri Nicoletti, Gabriele Brazzini, Francesca Piacentini, Sara Passerini, Dolores Limongi, Marco Ciotti, Anna Teresa Palamara, Girolama Alessandra Marfia, Valeria Pietropaolo
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Viruses
Subjects:
John Cunningham virus (JCPyV)
progressive multifocal leukoencephalopathy (PML)
multiple sclerosis (MS)
ocrelizumab
JCPyV DNA-detection
NCCR re-arrangements
Online Access:https://www.mdpi.com/1999-4915/13/9/1684

Internet

https://www.mdpi.com/1999-4915/13/9/1684

Similar Items